Volume of Retatrutide per 1 mg Dose
The volume of reconstituted retatrutide corresponding to 1 mg cannot be determined from the available evidence, as no FDA drug label, prescribing information, or guideline specifies the concentration or reconstitution instructions for this medication.
Critical Information Gap
No standardized concentration exists in the provided evidence. The research studies describe retatrutide dosing in milligrams (1 mg, 4 mg, 8 mg, 12 mg) administered subcutaneously once weekly, but none specify the volume or concentration of the injectable solution 1, 2.
Retatrutide remains investigational. The medication is currently in Phase 2 and Phase 3 clinical trials for obesity, type 2 diabetes, and chronic kidney disease 1, 2, 3. No FDA-approved prescribing information is available in the evidence provided.
Clinical Context from Available Research
Dosing regimens studied: Clinical trials evaluated subcutaneous doses ranging from 1 mg to 12 mg once weekly, with dose escalation strategies starting at 2 mg or 4 mg to mitigate gastrointestinal adverse events 1, 2.
Administration route: All studies administered retatrutide as a subcutaneous injection, but the specific volume per dose was not reported in the clinical trial publications 1, 2, 3.
Essential Action Required
You must obtain the actual product vial or prescribing information to determine:
- The concentration of retatrutide after reconstitution (e.g., mg/mL)
- The total volume in the vial
- Specific reconstitution instructions if supplied as lyophilized powder
Common pitfall: Assuming a standard concentration without verification can lead to significant dosing errors, particularly with investigational medications where formulations may vary between clinical trial sites or change during drug development.